Theorem, Charles River collaborate
CROs Theorem Clinical Research and Charles River Laboratories are collaborating to provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The alliance provides nonclinical testing programs in bioanalysis, immunogenicity and immunology to support clinical trials.
“Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples,” said Marc Hoffman, Theorem senior vice president and general manager of biopharmaceutical development.
Charles River’s research models, preclinical testing capabilities and clinical support services are backed by a bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped to measure drug and metabolite concentrations in biological matrices and to provide full support for capillary micro sampling and dried blood spot analysis. The variety of advanced equipment ensures the capacity to meet critical deadlines.